{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:54:15Z","timestamp":1791579255180,"version":"4.3.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001114","name":"Endocrine Society of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension with a prevalence of 14% in patients with newly diagnosed hypertension. Patients with PA experience a higher rate of cardiovascular events including stroke when compared to those with blood pressure matched essential hypertension. This systematic review and meta-analysis summarize current evidence on the prevalence of PA in patients with acute stroke or transient ischemic attack (TIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two reviewers independently reviewed the literature for observational studies on the prevalence of PA in patients with acute stroke or TIA. MEDLINE and Embase were searched for studies up to December 13, 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three single center studies conducted in Japan, Singapore and China were found to meet the inclusion criteria. The reported prevalence of PA in two cohort studies of adults with stroke or TIA were 3.1% and 4.0% and a third cross-sectional study in adults under 45 years old revealed a prevalence rate of 12.9%. Following a meta-analysis, the pooled prevalence of PA in adults with stroke or TIA is 5.8% [95% CI 1.6%-12.3%].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A considerable proportion of patients with stroke or TIA may have PA as the underlying cause of their hypertension. Given the increased risk of stroke associated with PA, clinicians should consider screening for PA in hypertensive patients with stroke or TIA. Further research is needed to evaluate the effect of timing and interfering medications on test results, which will inform an evidence-based approach to testing for PA following TIA or stroke.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42022328644.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1355398","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T09:08:50Z","timestamp":1709802530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of primary aldosteronism in acute stroke or transient ischemic attack: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Josephine","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Munnings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Clissold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh G.","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51438","article-title":"Detecting primary aldosteronism in Australian primary care: A prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.869980","article-title":"Primary aldosteronism more prevalent in patients with cardioembolic stroke and atrial fibrillation","volume":"13","author":"Nguyen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ando.2016.07.993","article-title":"Stroke disclosing primary aldosteronism: report on three cases and review of the literature","volume":"78","author":"Nasri","year":"2017","journal-title":"Annales d Endocrinol"},{"key":"B9","unstructured":"Clinical Guidelines for Stroke Management"},{"key":"B10","unstructured":"National Clinical Guideline for Stroke\n            TonyR\n          2016"},{"key":"B11","unstructured":"OrganisationES"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (Prisma-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"B14","volume-title":"JBI Manual for Evidence Synthesis","author":"Aromataris","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12883-016-0701-5","article-title":"Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization","volume":"16","author":"Miyaji","year":"2016","journal-title":"BMC Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"116774","DOI":"10.1016\/j.jns.2020.116774","article-title":"Primary aldosteronism in young adults with acute stroke: prevalence and clinical characteristics","volume":"413","author":"Tang","year":"2020","journal-title":"J Neurol Sci"},{"key":"B17","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022)","author":"Deeks JJ","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 Acc\/Aha\/Aapa\/Abc\/Acpm\/Ags\/Apha\/Ash\/Aspc\/Nma\/Pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.str.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.308398","article-title":"Stroke risk factors, genetics, and prevention","volume":"120","author":"Boehme","year":"2017","journal-title":"Circ Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8647026","article-title":"Age-related cutoffs of plasma aldosterone\/renin concentration for primary aldosteronism screening","volume":"2018","author":"Ma","year":"2018","journal-title":"Int J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1547","article-title":"Meta-analysis of prevalence: I2 statistic and how to deal with heterogeneity","volume":"13","author":"Migliavaca","year":"2022","journal-title":"Res Synthesis Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12298","article-title":"Raas and stress markers in acute ischemic stroke: preliminary findings","volume":"131","author":"Back","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.033159","article-title":"Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays","volume":"50","author":"Perschel","year":"2004","journal-title":"Clin Chem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.hyp.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684111","article-title":"The effect of antihypertensive medications on testing for primary aldosteronism","volume":"12","author":"Jedrusik","year":"2021","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac002","article-title":"International multicenter survey on screening and confirmatory testing in primary aldosteronism","volume":"188","author":"Naruse","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.14871","article-title":"Effects of ramipril on the aldosterone\/renin ratio and the aldosterone\/angiotensin ii ratio in patients with primary aldosteronism","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension (Dallas Tex: 1979)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: A systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"key":"B32","article-title":"[Screening tests and diagnostic examinations of hypertensives for primary aldosteronism]","volume":"54","author":"Omura","year":"2006","journal-title":"Rinsho Byori"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s1043-2760(01)00432-5","article-title":"Pathophysiological effects of aldosterone in cardiovascular tissues","volume":"12","author":"Rocha","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.281.3.R944","article-title":"Spironolactone reduces cerebral infarct size and Egf-receptor Mrna in stroke-prone rats","volume":"281","author":"Dorrance","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12342","article-title":"Aldosterone induces vascular damage","volume":"74","author":"Hung","year":"2019","journal-title":"Hypertension"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2014.11","article-title":"Endothelial dysfunction in patients with primary aldosteronism: A biomarker of target organ damage","volume":"28","author":"Liu","year":"2014","journal-title":"J Hum Hypertens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1055\/a-1141-5989","article-title":"Atrial fibrillation in primary aldosteronism","volume":"52","author":"Pan","year":"2020","journal-title":"Horm Metab Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.08.022","article-title":"Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural\/electrical remodeling","volume":"168","author":"Mayyas","year":"2013","journal-title":"Int J Cardiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000002250","article-title":"Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (Papphy) study","volume":"38","author":"Seccia","year":"2020","journal-title":"J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1355398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T09:09:02Z","timestamp":1709802542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1355398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":40,"alternative-id":["10.3389\/fendo.2024.1355398"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1355398","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"article-number":"1355398"}}